Mayne Pharma Group Limited (ASX:MYX)
Australia · Delayed Price · Currency is AUD 3.250
+0.170 (5.52%)
Nov 9, 2026, 10:47 AM AEDT
Mayne Pharma Group Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Mayne Pharma Group stock has a consensus rating of "Buy" and an average price target of $4.37. The average 1-year stock price forecast is 34.37% higher than the current stock price, while the lowest is $3.65 (+12.31%) and the highest is $5.25 (+61.54%).
Price Target: $4.37 (+34.37%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Mayne Pharma Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Mar '26 | Apr '26 | Jul '26 | Aug '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 1 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ord Minnett No rating | Ord Minnett | Buy Maintains $4.20 | Buy | Maintains | $4.20 | +29.23% | Oct 27, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $3.83 → $3.75 | Buy | Maintains | $3.83 → $3.75 | +15.38% | Aug 27, 2026 |
Financial Forecast
Revenue This Year
382.77M
from 383.68M
Decreased by -0.24%
Revenue Next Year
392.41M
from 382.77M
Increased by 2.52%
EPS This Year
-0.45
from -0.78
EPS Next Year
-0.38
from -0.45
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.